BioDlink International Co Ltd
01875
Company Profile
Business description
BioDlink International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families, as well as medical professionals. The company has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The company generates maximum revenues from Mainland China.
Contact
120 Changyang Street
Suzhou Industrial Park
Suzhou215024
CHNT: +86 51262965186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
611
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
stocks
A 5-Star US stock to buy with a near-5% yield
Undervalued by 23%, this cheap dividend stock is a top pick in its sector.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.70 | 47.60 | 0.52% |
| CAC 40 | 7,870.68 | 75.26 | 0.97% |
| DAX 40 | 23,739.47 | 204.64 | 0.87% |
| Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
| FTSE 100 | 9,284.83 | 70.85 | 0.77% |
| HKSE | 26,393.92 | 265.72 | 1.02% |
| NASDAQ | 22,484.07 | 99.37 | 0.44% |
| Nikkei 225 | 44,926.34 | 428.65 | -0.95% |
| NZX 50 Index | 13,238.55 | 126.82 | 0.97% |
| S&P 500 | 6,643.70 | 38.98 | 0.59% |
| S&P/ASX 200 | 8,864.30 | 53.60 | 0.61% |
| SSE Composite Index | 3,814.83 | 13.28 | -0.35% |